Oncotech | GenomeWeb

Oncotech

The bank, formerly owned by Oncotech, contains more than 144,000 discrete cancer samples.

No mention was made of a number of other miRNA diagnostics projects, suggesting that the Danish company has put these on hold as part of a scale-back of its efforts in the area.

Despite the setback, Exiqon remains on track with its strategy of marketing its microRNA-based diagnostics in collaboration with partners, and expects to announce a deal before the end of the year, a company official said.

The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.